A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantation

Transplantation Proceedings

Volumn 37, Issue 2, 2005, Pages 1289-1290

  Lo, A ^a   Stratta, R J ^b   Alloway, R R ^c   Hodge, E E ^d  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; AFRICAN AMERICAN; ANALYTIC METHOD; CAUSE OF DEATH; CLINICAL TRIAL; CONFERENCE PAPER; ETHNOLOGY; GRAFT FAILURE; HLA MATCHING; HUMAN; KIDNEY TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; ORGAN DONOR; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; RISK ASSESSMENT; STATISTICAL MODEL; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

EID: 17844394725     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.12.212     Document Type: Conference Paper

References (3)

1. F. Saudek, J. Malaise, T. Berney Influence of HLA compatibility in primary simultaneous pancreas-kidney (SPK) transplantation: Results at 1 year of a large multicentre trial Am J Transplant 3 suppl 5 2003 255 A 406
2. S.K. Takemoto HLA matching in the new millennium J.M. Cecka P.I. Terasaki Clinical Transplants 2003 2004 UCLA Immunogenetics Center Los Angeles, Calif 387
3. R.J. Stratta, R.R. Alloway, A. Lo Two dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study Transplantation 75 2003 1260